Education
About Us
Working with TipRanks
Follow Us
Indaptus Therapeutics (INDP)
NASDAQ:INDP
INDP Stock Chart & Stats
$2.55
-$0.06(-5.94%)
At close: 4:00 PM EST
$2.55
-$0.06(-5.94%)
Day’s Range― - ―
52-Week Range$1.65 - $47.60
Previous CloseN/A
Volume47.54K
Average Volume (3M)1.08M
Market Cap
$4.47M
Enterprise Value$6.43M
Total Cash (Recent Filing)$5.83M
Total Debt (Recent Filing)$8.69K
Price to Earnings (P/E)―
Beta2.13
Next Earnings
Mar 12, 2026EPS Estimate
-4.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.98
Shares Outstanding1,751,163
10 Day Avg. Volume869,867
30 Day Avg. Volume1,084,648
Financial Highlights & Ratios
PEG Ratio1.17
Price to Book (P/B)55.92
Price to Sales (P/S)0.00
P/FCF Ratio-17.90
Enterprise Value/Market Cap1.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.38
Forecast
1Y Price Target
$10.00Price Target Upside292.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe combination study of Decoy and tislelizumab is ongoing, with positive safety results so far, which is promising for the treatment of solid tumors.
Safety ProfileDecoy therapy uses a nonpathogenic strain of bacteria, reducing endotoxin levels significantly, which enhances its safety profile.
Therapeutic DevelopmentMaintain a Buy rating given the Decoy20 opportunity in solid tumors, which has shown positive safety data thus far.
Bears Say
Capital RequirementsIndaptus will need to raise additional capital to continue the clinical development of its Decoy immune therapy.
Financial PerformanceIndaptus reported 3Q25 results with a net loss of ($2.9M) and ended the period with $5.8M in cash on the balance sheet, which the company expects to provide runway into 1Q26.
Stock ValuationBased on near-term capital needs and expectations of additional dilution from future raises, the 12-month price target is lowered to $10, from $25.
Indaptus Therapeutics News
INDP FAQ
What was Indaptus Therapeutics’s price range in the past 12 months?
Indaptus Therapeutics lowest stock price was $1.65 and its highest was $47.60 in the past 12 months.
What is Indaptus Therapeutics’s market cap?
Indaptus Therapeutics’s market cap is $4.47M.
When is Indaptus Therapeutics’s upcoming earnings report date?
Indaptus Therapeutics’s upcoming earnings report date is Mar 12, 2026 which is in 73 days.
How were Indaptus Therapeutics’s earnings last quarter?
Indaptus Therapeutics released its earnings results on Nov 12, 2025. The company reported -$2.98 earnings per share for the quarter, beating the consensus estimate of -$4.17 by $1.19.
Is Indaptus Therapeutics overvalued?
According to Wall Street analysts Indaptus Therapeutics’s price is currently Undervalued.
Does Indaptus Therapeutics pay dividends?
Indaptus Therapeutics does not currently pay dividends.
What is Indaptus Therapeutics’s EPS estimate?
Indaptus Therapeutics’s EPS estimate is -4.36.
How many shares outstanding does Indaptus Therapeutics have?
Indaptus Therapeutics has 1,751,163 shares outstanding.
What happened to Indaptus Therapeutics’s price movement after its last earnings report?
Indaptus Therapeutics reported an EPS of -$2.98 in its last earnings report, beating expectations of -$4.17. Following the earnings report the stock price went up 6.25%.
Which hedge fund is a major shareholder of Indaptus Therapeutics?
Currently, no hedge funds are holding shares in INDP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Indaptus Therapeutics
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
INDP Stock 12 Month Forecast
Average Price Target
$10.00
▲(292.16% Upside)
Technical Analysis
Palisade Bio
―
Alaunos Therapeutics
―
―
Xenetic Biosciences
―
Longevity Health Holdings
―
Ownership Overview
3.83% Insiders
0.23% Mutual Funds
1.08% Other Institutional Investors
94.82% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---